Espicom


The Pharmaceutical Market: Chile

Published 08 October 2014

  • 129 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Chile

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Chile 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Chile 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Chile 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Chile 2010-2018)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Chile 2010-2018)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Chile 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Chile 2012-2018)
31
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
34
Table: Economic Activity (Chile 2009-2018)
39
Industry Risk Reward Ratings
40
Americas Risk/Reward Ratings
40
Chile Risk/Reward Ratings
46
Rewards
46
Risks
47
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Healthcare Sector
51
Table: Isapres Beneficiaries, 1990-2009
52
Table: Beneficiaries by Isapre Type, 2009
54
Healthcare Sector Developments
59
Table: Physicians by Specialty, 2000-2009
62
Healthcare Insurance
62
Research And Development
65
Clinical Trials
67
Regulatory Development
69
Regulatory Regime
69
Regulatory Developments
70
Table: Latin American Regulations On Bioequivalence And GMP
78
Intellectual Property Issues
78
Trade Agreements
81
Pricing Regime
83
Public Procurement
84
Table: Pharmaceutical Price Build-up (%)
85
Reimbursement Regime
85
Competitive Landscape
87
Pharmaceutical Sector
87
Domestic Industry
87
Foreign Industry
88
Pharmaceutical Distribution
90
Pharmaceutical Retail Sector
90
Table: Pharmacy Sales Value by Sector, 2007-2008 (USDmn)
94
Company Profile
95
Laboratorios Chile (LabChile)
95
Corporaci-n Farmac-utica Recalcine (CFR)
98
Laboratorios Andr-maco
103
Pfizer
107
Novartis
109
Sanofi
111
GlaxoSmithKline
113
Merck & Co
115
Other Company Developments
117
Demographic Forecast
118
Demographic Outlook
118
Table: Chile's Population By Age Group, 1990-2020 ('000)
119
Table: Chile's Population By Age Group, 1990-2020 (% of total)
120
Table: Chile's Key Population Ratios, 1990-2020
121
Table: Chile's Rural And Urban Population, 1990-2020
121
Glossary
122
Methodology
124
Pharmaceutical Expenditure Forecast Model
124
Healthcare Expenditure Forecast Model
124
Notes On Methodology
125
Risk/Reward Ratings Methodology
126
Ratings Overview
127
Table: Pharmaceutical Risk/Reward Ratings Indicators
127
Indicator Weightings
128
OVERVIEW OF THE PHARMACEUTICAL MARKET IN CHILE

Pharmaceutical companies will continue to look to fast growing emerging markets for revenue growth, and we believe that Latin American economies, with rising incomes, ageing populations and increased spending on healthcare will provide significant opportunities. Indeed, it is our view that emerging markets will be the main drivers of the pharmaceutical sector's expansion over the coming years as growth in traditional markets such as the US, Western Europe and Japan remains lacklustre. We note however, that imported patented and high-cost drugs, mostly originating from Europe and the US, account for a significant portion of the Latin American pharmaceutical market in terms of value.

Headline Expenditure Projections

Pharmaceuticals: CLP1,508bn (US$3.12bn) in 2011 to CLP1,642bn (US$3.22bn) in 2012; +8.9% in local currency terms and +3.3% in US dollar terms.

Healthcare: CLP9,034bn (US$18.67bn) in 2011 to CLP9,941bn (US$19.49bn) in 2012; +10.0% in local currency terms and +4.4% in US dollar terms.

Medical devices: CLP256.33bn (US$530mn) in 2011 to CLP267.45bn (US$525mn) in 2012; +4.3% in local currency terms and -1.0% in US dollar terms.


Risk/Reward Rating

In Q4 12's America's pharmaceutical risk/reward ratings (RRRs) matrix, Chile ranks in seventh place out of the 17 countries surveyed, scoring a total of 53.7 out of 100. We expect Chile, which has a favourable rewards profile, to climb up the regional matrix over the coming years as operational risks become addressed. In the Q412 RRRs, with regards to the country's attractiveness to innovative drug companies, Chile stands above Argentina and Peru and below Mexico and Brazil.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%